<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684784</url>
  </required_header>
  <id_info>
    <org_study_id>DNEMG</org_study_id>
    <nct_id>NCT04684784</nct_id>
  </id_info>
  <brief_title>Effect of Dry Needling on Surface Electromyographic Activity in Latent Trigger Points</brief_title>
  <official_title>Effect of Dry Needling on Surface Electromyographic Activity in Latent Trigger Points</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Castilla-La Mancha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Castilla-La Mancha</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brief summary: The purpose of this study is to determine the effect of Dry Needling (DN) on&#xD;
      electromyographic activity in different situations at the latent trigger point (LTrP) point&#xD;
      of the upper trapezius. Randomized controlled trial, in parallel with the crossover control&#xD;
      design. Two groups with LTrP in the upper trapezius, and the DN group or the Sham-Dn group&#xD;
      will be randomly selected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Actual">February 18, 2021</completion_date>
  <primary_completion_date type="Actual">February 4, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in resting surface EMG activity (amplitude, RMS)</measure>
    <time_frame>Baseline, at 30 minutes after treatment, at 24 hours after treatment, at 72 hours after treatment</time_frame>
    <description>EMG activity (RMS) of the upper trapezius after dry needling or sham needling as assessed by the EMG ME 6000 TE(Mega Electronics, Kuopio, Finland). Resting EMG activity will be expressed as a percentage of maximal reference contractions of the upper trapezius (% reference contractions).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in resting surface EMG activity (Median frequency, MF)</measure>
    <time_frame>Baseline, at 30 minutes after treatment, at 24 hours after treatment, at 72 hours after treatment</time_frame>
    <description>EMG activity (RMS) of the upper trapezius after dry needling or sham needling as assessed by the EMG ME 6000 TE(Mega Electronics, Kuopio, Finland).&#xD;
EMG median frequency will be used to determine the endurance of the upper trapezius. The EMG median frequency will be measured in Hertz (Hz).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in submaximal contrations surface EMG activity of upper trapezius (amplitude, RMS)</measure>
    <time_frame>Baseline, at 30 minutes after treatment, at 24 hours after treatment, at 7submaximal contractions EMG activity will be expressed as a percentage of maximal reference contractions of the upper trapezius (% reference contractions).2 hours after treatment</time_frame>
    <description>EMG activity (RMS) of the upper trapezius after dry needling or sham needling as assessed by the EMG ME 6000 TE(Mega Electronics, Kuopio, Finland).&#xD;
EMG activity of submaximal contractions will be expressed as a percentage of submaximal reference contractions of the upper trapezius (% reference contractions).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in submaximal contrations surface EMG activity of upper trapezius (Median frequency, MF)</measure>
    <time_frame>Baseline, at 30 minutes after treatment, at 24 hours after treatment, at 72 hours after treatment</time_frame>
    <description>EMG activity (RMS) of the upper trapezius after dry needling or sham needling as assessed by the EMG ME 6000 TE(Mega Electronics, Kuopio, Finland).&#xD;
EMG median frequency will be used to determine the endurance of the upper trapezius. The EMG median frequency will be measured in Hertz (Hz).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Pressure Threshold (PPT)</measure>
    <time_frame>Baseline, at 30 minutes after treatment, at 24 hours after treatment, at 72 hours after treatment</time_frame>
    <description>Pressure-Pain Threshold as assessed by an manual mechanical algometer. PPT is the minimal amount of pressure that produces pain and is used to assess abnormalities in nociceptive processing or hyperalgesia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Trigger Point Pain, Myofascial</condition>
  <arm_group>
    <arm_group_label>Deep Dry Needling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Dry Needling</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intervention-Dry Needling</intervention_name>
    <description>Deep Dry Needling into the site of the latent TriggerPoint of the upper trapezius muscle. 1 session in upper trapezius muscle moving the needle up and down ten times.</description>
    <arm_group_label>Deep Dry Needling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control-Dry Needling</intervention_name>
    <description>Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles</description>
    <arm_group_label>Sham Dry Needling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 30 years&#xD;
&#xD;
          -  The presence of LTrP in the middle third of the upper trapezius muscle onthe dominant&#xD;
             side&#xD;
&#xD;
          -  Being able to provide written informed consent&#xD;
&#xD;
          -  Being able to follow instructions and realize clinical tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any pharmacological therapeutic&#xD;
&#xD;
          -  Any medical treatment or physical therapies at cervical region during the 6-month&#xD;
             before this study&#xD;
&#xD;
          -  Any diagnosed health problem&#xD;
&#xD;
          -  Any history of head and upper extremity surgery or trauma&#xD;
&#xD;
          -  Any red flags to DN, (ie: metabolic diseases, pregnancy, kinesiophobia,Infection,&#xD;
             cancer)• Absence of recurrent history of neck pain&#xD;
&#xD;
          -  No neck pain symptomatology the previous 6 months&#xD;
&#xD;
          -  Cervical disk herniation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Abián-Vicén, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Castilla-La Mancha</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Performance and Sport Rehabilitation Laboratory</name>
      <address>
        <city>Toledo</city>
        <zip>45071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry needling</keyword>
  <keyword>Electromyography</keyword>
  <keyword>Latent trigger point</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

